

1 **Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet**
2 **Nam: a modeling analysis**

3 David Coomes^{1,2}, Dylan Green^{1,2}, Ruanne Barnabas^{1,2,3}, Monisha Sharma², Magdalena Barr-DiChiara⁴,
4 Muhammad S. Jamil⁴, Rachel Baggaley⁴, Morkor Newman Owiredu⁴, Virginia Macdonald⁵, Van Nguyen⁶, Son
5 Vo Hai⁷, Melanie M. Taylor^{4,8}, Teodora E Wi⁹, Cheryl Johnson^{5,10}, Alison L. Drake^{1,2§}

6
7 1. University of Washington, Department of Epidemiology, Seattle, WA, USA

8 2. University of Washington, Department of Global Health, Seattle, WA, USA

9 3. University of Washington, Department of Medicine, Seattle, WA, USA

10 4. Department of Global Programmes of HIV, Hepatitis and HIV, World Health Organization, Geneva,
11 Switzerland

12 5. Headquarters, World Health Organization, Geneva, Switzerland

13 6. Viet Nam Country Office, World Health Organization, Hanoi, Viet Nam

14 7. Viet Nam Authority for HIV/AIDS Prevention and Control, Ministry of Health, Hanoi, Viet Nam

15 8. Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

16 9. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland

17 10. Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United
18 Kingdom

19
20 § Corresponding author: Alison L. Drake

21 325 9th Avenue

22 Box 359909

23 Seattle, WA 98195, USA

24 Phone: 1-206-543-5847

25 Email: adrake2@uw.edu

26
27
28
29 Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the
30 official position of the World Health Organization or the United States Centers for Disease Control
31

32
33
34
35
36 Word count: 3,652

37 Abstract word count: 247

38 Keywords: HIV testing, syphilis testing, key populations, 95-95-95

39 **ABSTRACT**

40 **Objectives**

41 Key populations, including sex workers, men who have sex with men, and people who inject drugs, have a high
42 risk of HIV and sexually transmitted infections (STIs). We assessed the health and economic impacts of
43 different HIV and syphilis testing strategies among three key populations in Viet Nam using a dual HIV/syphilis
44 rapid diagnostic test (RDT).

45 **Setting**

46 We used the Spectrum AIDS Impact Model to simulate the HIV epidemic in key populations in Viet Nam and
47 evaluated five testing scenarios. We used a 15-year time horizon and all costs are from the provider's
48 perspective.

49 **Participants**

50 We include the entire population of Viet Nam in the model.

51 **Interventions**

52 We model five testing scenarios among key populations: 1) annual testing with an HIV rapid diagnostic test
53 (RDT), 2) annual testing with a dual RDT, 3) biannual testing using dual RDT and HIV RDT, 4) biannual
54 testing using HIV RDT, and 5) biannual testing using dual RDTs.

55 **Primary and secondary outcome measures**

56 The primary outcome is incremental cost-effectiveness ratios (ICERS). Secondary outcomes include HIV and
57 syphilis cases and costs for each proposed intervention.

58 **Results**

59 Annual testing using a dual HIV/syphilis RDT was cost saving and averted 3,206 HIV cases and treated 7,719
60 syphilis cases compared to baseline over 15 years. Biannual testing using one dual test and one HIV RDT, or
61 two dual tests both averted an additional 875 HIV cases and were cost-effective (\$1,024 and \$2,518 per DALY
62 averted, respectively). Annual or biannual HIV testing using HIV RDTs and separate syphilis tests were more
63 costly and less effective than using one or two dual RDTs.

64 **Conclusions**

65 Annual or biannual HIV and syphilis testing using dual RDTs among key populations can be cost-effective and
66 support countries in reaching global reduction goals for HIV and syphilis.

67 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 68 • Strength: Our model presents novel cost-effectiveness estimates for the use of dual HIV/syphilis testing
69 in key populations that can inform health planners
- 70 • Strength: We include five testing scale up scenarios using both HIV RDT and dual HIV/syphilis RDT
- 71 • Strength: Our model is informed by demographic, behavioral, and biological data from government
72 sources, surveys, surveillance, publicly available reports, databases, and peer-reviewed literature
- 73 • Limitation: We made some assumptions regarding the timing and uptake of HIV and syphilis testing
74 among key populations that may be inaccurate.
- 75 • Limitation: Our model assumes that increased syphilis testing and treatment will not impact syphilis
76 prevalence, however, it is unknown whether increased testing will reduce or increase syphilis
77 prevalence.

78

79

80 INTRODUCTION

81 Key populations, including people who inject drugs (PWID), men who have sex with men (MSM), sex workers
82 (SW), and transgender populations, are at higher risk of acquiring both HIV and syphilis. HIV incidence is
83 significantly higher among key populations in all regions compared to the general population; however,
84 differences vary substantially by region and by key population.[1] While key populations represent 25% of new
85 HIV cases in sub-Saharan Africa, they represent 80% of new HIV cases in the rest of the world.[2] Recent data
86 suggests syphilis incidence, while remaining prevalent in low- and middle-income countries (LMIC), is increasing
87 among key populations, particularly MSM.[1, 3, 4] World Health Organization (WHO) HIV testing guidelines
88 recommend HIV retesting at least annually for key populations and more frequent testing (3-6 months) for those
89 with high ongoing risk.[5] WHO guidelines for syphilis screening depend on population and setting. Rapid
90 diagnostic tests (RDTs) are increasingly being used to screen for syphilis in some settings, yet laboratory-based
91 testing remains common,[6] leaving many key populations unreached by syphilis testing. With the introduction
92 of prequalified dual HIV/syphilis RDTs, and the recent WHO recommendation to offer dual HIV/syphilis testing
93 in antenatal care (ANC) settings,[7] it is important to consider how further integration and expansion of dual
94 HIV/syphilis testing could benefit key populations.

95 Since 2015, WHO has recommended immediate initiation of antiretroviral therapy (ART) for all people living
96 with HIV (PLHIV) [8] and the United Nations 95-95-95 targets aim to diagnose 95% of PLHIV, provide 95% of
97 PLHIV with ART, and ensure 95% PLHIV on ART are virally suppressed.[9] Despite progress towards these
98 goals – in 2019 81% of PLHIV knew their HIV status and 67% were on ART – this progress is uneven; only 2/3
99 of key populations are aware of their HIV status.[2] While key populations lag behind the general population in
100 all phases of testing, linkage to treatment, and viral suppression, the largest gap exists in testing.[10] WHO has
101 also developed a global strategy on sexually transmitted infections (STIs) which aims for a 90% reduction in
102 syphilis incidence by 2030, and for 70% of key populations to have access to STI and HIV services, including
103 prevention, testing, and treatment.[11] Increased syphilis testing and treatment may reduce syphilis burden among
104 key and general populations, as well as HIV incidence since early symptomatic syphilis increases risks of HIV

105 acquisition and transmission.[3] Currently, the frequency of syphilis testing recommended by WHO is based on
106 local epidemics; however, the optimal frequency for syphilis testing among key populations is unknown.

107 In Viet Nam, the national HIV prevalence is <1% in the general population, and significantly higher in key
108 populations, with prevalence ranging between 3-13% among PWID, MSM, and FSW. Similarly, syphilis
109 prevalence among MSM (6.7%) and FSW (2.1%) are also higher than the general population (0.3%).[12] With
110 budgetary constraints in HIV and STI programs, and the health sector, identifying cost-effective strategies for
111 targeted HIV and syphilis testing among high risk groups in Viet Nam is crucial to inform policymakers seeking
112 to optimize resource allocation to maximize population health. We modeled the health impacts and costs
113 associated with varying frequencies of HIV and syphilis testing for key populations, using test scenarios that
114 include a dual HIV/syphilis RDT.

115 **METHODS**

117 **Settings and Populations**

118 We modeled three key populations: MSM, PWID, and FSW (and their clients) in Viet Nam, using national level
119 HIV prevalence and syphilis prevalence estimates for each key population (**Table 1**).

120 **Table 1. Model parameters for Spectrum input and cost-effectiveness analysis of HIV and syphilis testing**
121 **scale up among key populations in Viet Nam.** ^a = 2018 Viet Nam HIV Sentinel Surveillance. ^b = 2019 Viet Nam
122 HIV Sentinel Surveillance. * = Spectrum model prior. ** = assumed. *** = Based on information from in-
123 country source.

Model parameter	Value
HIV Prevalence	
MSM (incl. TGW) ^a	10.8%
PWID ^b	12.7%
FSW ^a	3.6%
Syphilis Prevalence[12]	
MSM (incl. TGW)	6.7%
PWID	0.3%
FSW	2.1%
Baseline syphilis test acceptance	
MSM (incl. TGW)[45],[46],[14]	27%
PWID[15]	16%
FSW[16],[47]	35%

Syphilis DALYs averted[48]	
DALYs averted per syphilis case treated	0.04
ART	
2019 Coverage***	70%
Annual Scale-Up**	4.8%
Transmission Reduction Efficacy*	70%
Mortality Reduction Efficacy*	80%
Other Prevention	
Condom Use**	50%
Condom Efficacy*	80%
PrEP Coverage (MSM incl. TGW)**	5%
PrEP Efficacy*	90%
PrEP Adherence*	80%
Costs***	
HIV Lay Test†	\$4.50
Syphilis RPR†	\$6.28
HIV/Syphilis Dual Test†	\$6.50
ART‡	\$285
Syphilis Treatment	\$6.50
Time Horizon	2020 - 2035
Discount Rate	3%

124 † Testing costs include labor, incentives, travel costs, and test kits. Primary cost driver between tests is the cost of the test kit.

125 ‡ ART cost includes labor, laboratory monitoring costs, ARVs, and other recurring costs.

126 * MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, TGW=transgender women,
 127 ART=antiretroviral therapy, PrEP=pre-exposure prophylaxis, syphilis RPR=syphilis rapid plasma regain.

129 Model

130 We used a deterministic, compartmental model to simulate the HIV epidemic in key populations from 2020-2035
 131 using the AIDS Impact Model within the Spectrum software package (v 5.76). The model estimates annual HIV
 132 incidence, AIDS mortality, and disability. We simulated the impact of increasing HIV testing frequency using the
 133 Goals model within Spectrum, as previously described.[13] Briefly, the model is age- and sex-stratified with
 134 compartments for MSM, PWID, FSW and their clients, and low- and medium-risk heterosexuals.¹ The model was
 135 parameterized with demographic, behavioral, and biological data from government sources, surveys, surveillance,
 136 publicly available reports, databases, and peer-reviewed literature. To estimate syphilis burden, we used
 137 population size estimates from the Goals model and population-specific estimates of prevalence;[12] we estimate

¹ Low-risk heterosexuals are those in stable couples while medium-risk heterosexuals are those that engage in casual sex but are not in a high-risk group (high risk groups: MSM, FSW, PWID).

138 the number of persons tested positive and treated for syphilis infection under each scenario. This model assumes
139 that syphilis testing and treatment does not impact syphilis prevalence. For both HIV and syphilis, disability-
140 adjusted life years (DALYs) are calculated for each scenario. Model key parameters are shown in **Table 1**.

141 **Costs**

142 Cost inputs include cost per HIV test, initial syphilis test (rapid plasma reagin (RPR)), and the dual HIV/syphilis
143 RDT. We used local data on the personnel, commodities, and transport costs associated with lay testing and
144 estimate costs (**Table 1**). ART costs include personnel, commodities, clinical follow-up, and laboratory
145 monitoring. This analysis includes the costs of intervention delivery and treatment (penicillin and ART) but does
146 not consider additional averted sequelae costs such as the treatment of opportunistic infections due to uncontrolled
147 HIV. All costs are from the provider's perspective and reported in 2019 US dollars.

148 **Scenarios**

149 Our baseline scenario estimates annual HIV testing based on current WHO recommendations,[5] and syphilis
150 testing based on observed uptake. In the baseline scenario, we assume 50% of individuals in key populations test
151 annually for HIV, and syphilis testing with RPR occurs at rates specific to each key population (**Table 2**).[14–
152 16] We considered alternative scenarios with varying testing frequency and test type (separate HIV and syphilis
153 RPR, or a combined dual syphilis/HIV RDT) among key populations from 2020 to 2035. Scenarios modeled
154 include: **1)** annual HIV testing with RDT and baseline syphilis RPR testing, **2)** annual testing with dual RDT, **3)**
155 biannual testing (2 times per year), first with dual RDT and then with HIV RDT, **4)** biannual HIV testing with
156 RDT and baseline syphilis RPR testing, and **5)** biannual testing with dual RDT (**Table 2**). We assumed 75% test
157 acceptance for the first test in all scenarios except baseline, and 90% of those who accepted the first test would
158 accept the second test in all scenarios that include biannual testing.

159
160
161
162
163

Table 2: HIV/syphilis testing scenarios among key populations in Viet Nam. The table cells show the proportion of key populations in Viet Nam that receive each test per year. If not specified, the proportion refers to all key populations.

Scenario	Proportion of key population receiving HIV or syphilis testing per year			
	1 HIV test	2 HIV tests	1 syphilis test	2 syphilis tests
Baseline	50%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
1. One HIV RDT	75%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
2. One Dual HIV/syphilis RDT	75%		75%	-
3. One HIV RDT & One Dual HIV/syphilis RDT	75%	68%	75%	-
4. Two HIV RDTs	75%	68%	35% (FSW), 27% (MSM), 16% (PWID)	-
5. Two Dual HIV/syphilis RDT	75%	68%	75%	68%

* MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, RDT=rapid diagnostic test.

We modeled increases in testing coverage by adjusting the percent of adults living with HIV (PLWH) on ART. The baseline scenario assumes 95% ART coverage among PLWH by 2028 (4.8% increase per year) based on recent ART scale-up in Viet Nam; test coverage increases by 6.0% per year with annual HIV testing (HIV RDT or dual RDT), and by 7.2% per year with biannual testing. Maximum test coverage is 95% for each model. All models assume ART coverage of 66% of men and 72% of women living with HIV in 2020 based on estimates from the Viet Nam HIV-AIDS Technical Working Group (TWG). We assume universal treatment among those who test positive for syphilis, individuals treated cannot become re-infected within the same year,[17] and no changes to syphilis prevalence under test case scenarios.

Cost-Effectiveness

Health impact was measured in DALYs averted, HIV infections averted, syphilis infections treated, and AIDS-related deaths averted over the 15-year time horizon. This time horizon was chosen because it reflects current HIV program planning in Viet Nam. Costs and health benefits were discounted at 3% annually per standard health economic evaluations. Incremental costs were calculated as costs incurred and averted by the testing strategy. We

utilized WHO guidelines for cost-effectiveness threshold: less than gross domestic product (GDP) per capita is considered cost-effective in Viet Nam (\$2,715 USD in 2019).[18]

Model calibration and sensitivity analyses

Models were calibrated to national HIV prevalence estimates for each key population. Monte Carlo sensitivity analyses were conducted to evaluate robustness of results to changes in: HIV and syphilis testing coverage, scenario program uptake rate, HIV and syphilis testing cost, HIV and syphilis treatment cost, average years on ART, and time horizon. **Table S1** shows the model parameters, ranges, and distributions used in the sensitivity analysis.

Patient and public involvement

It was not appropriate or possible to involve patients or the public in the design, conduct, reporting, or dissemination plans of our research.

Ethics approval

This study did not receive nor require ethics approval as it does not involve human or animal participants.

RESULTS

Increasing annual HIV test coverage from 50% (baseline) to 75% using an HIV RDT (scenario 1) or a dual RDT (scenario 2) is projected to avert 3,206 HIV infections and 660 AIDS-related deaths by 2035 in Viet Nam (**Table 3**). Annual testing using dual RDT led to treatment of an additional 7,719 syphilis cases over 15 years compared to using HIV RDT, but the number of HIV infections averted was the same. HIV testing with either HIV or dual RDT biannually (scenarios 3, 4, & 5) was projected to avert an additional 875 HIV infections and 183 AIDS-related deaths by 2035 compared to annual testing. Testing using a dual HIV/syphilis RDT biannually among key populations is projected to lead to an additional 124,460 syphilis cases treated by 2035, compared to annual testing using a dual RDT (116,680 total syphilis cases treated).

205
206
207
208
209

Table 3. Estimated HIV and syphilis infections, and cost-effectiveness of increased HIV and Dual HIV/syphilis testing among key populations in Viet Nam from 2020-2035. Each scenario refers to the number of tests per year. The baseline scenario assumes that 50% of key populations are tested for HIV each year and syphilis testing rates are specific to each sub-population (FSW, MSM, and PWID). Scenarios including one test per year assume a 75% test acceptance rate, and those that include two tests per year assume a 75% test acceptance rate for the first test, and a 68.5% test acceptance rate for the second test. *Incremental cases averted, Total DALYs averted, and ICERs* compare each scenario to the previous one.

		Scenario					
		Baseline	1 Dual Test	1 HIV Test	1 HIV & 1 Dual	2 HIV Tests	2 Dual Tests
HIV	New HIV infections	57,902	54,696	54,696	53,821	53,821	53,821
	AIDS deaths	13,877	13,217	13,217	13,034	13,034	13,034
	Total HIV DALYs	174,567,240	174,508,007	174,508,007	174,490,608	174,490,608	174,490,608
Syphilis	Total cases treated	108,901	116,680	108,901	116,680	108,901	233,361
	Total DALYs treated	3,466	3,713	3,466	3,713	3,466	7,426
Incremental cases averted	HIV infections averted	-	3,206	0	875	0	0
	HIV DALYs averted	-	59,233	0	17,399	0	0
	Syphilis cases treated	-	7,779	-7,779	7,779	-7,779	124,460
	Syphilis DALYs averted	-	248	-248	248	-248	7,426
Total DALYs averted (HIV & Syphilis)		-	-	59,481	-248	17,647	-248
Costs (USD)	Net Costs	\$34,795,660	\$30,123,774	\$36,853,771	\$47,943,060	\$54,673,057	\$57,292,031
	HIV testing	\$16,491,955	-	\$24,683,204	\$19,677,541	\$44,360,744	-
	HIV treatment averted	-	-\$6,133,138	-\$6,133,138	-\$7,991,393	-\$7,991,393	-\$7,991,393
	Syphilis testing	\$17,740,540	-	\$17,740,540	-	\$17,740,540	-
	Syphilis treatment	\$563,165	\$603,395	\$563,165	\$603,395	\$563,165	\$1,206,793
	Dual testing	-	\$35,653,516	-	\$35,653,516	-	\$64,076,631
Total incremental costs		-	-\$4,671,887	\$6,729,997	\$11,089,289	\$6,729,997	\$2,618,974
ICERs (cost per DALY averted)		-	Cost-saving	<i>Dom</i>	\$1,024	<i>Dom</i>	\$2,518

210
211
212

*DALY=disability adjusted life-years, USD=United States dollars, ICERs=incremental cost-effectiveness ratios, FSW=female sex workers, MSM=men who have sex with men, PWID=people who inject drugs

213 The most effective strategy was biannual testing with the dual RDT, which was projected to avert 4,081
214 HIV infections (7% of total infections), 76,632 HIV DALYs (0.04% of total HIV DALYs), and treat
215 124,460 cases of syphilis by 2035 compared to the baseline scenario. The discounted cost of implementing
216 this scenario over 30 years is \$57.3 million USD compared to \$34.8 million USD for the baseline scenario.
217 The testing cost of implementing biannual testing using the dual RDT is almost four times the cost of
218 baseline testing with an HIV RDT (\$64.1 million vs. \$16.5 million, respectively), but an estimated \$8.0
219 million USD in HIV treatment costs would be saved by biannual HIV testing, and \$17.7 million USD in
220 syphilis testing costs would be averted by using the dual RDT. The cost of biannual testing with an HIV
221 RDT and continuing to test for syphilis with RPR is slightly higher than biannual testing with the dual
222 RDT (\$57.3 vs. \$54.7 million USD, respectively), but the latter strategy treats an estimated 124,000 more
223 cases of syphilis over 15 years.

224 Annual testing with the dual RDT is cost saving compared to the baseline scenario (**Figure 1**). Annual
225 HIV testing with RDT is more expensive and averts fewer DALYs than with the dual RDT (strongly
226 dominated). The next most efficient scenario is biannual testing using one dual RDT and one HIV RDT,
227 which is cost-effective (\$1,024 USD per DALY averted). Biannual testing with the dual RDT is also cost-
228 effective (\$2,518 USD per DALY averted) and more cost-effective than using the HIV RDT (weakly
229 dominated). Despite slightly higher initial costs, the discounted cost of annual testing with a dual RDT
230 becomes less than that of current testing within two years, due to decreased ART costs associated with
231 HIV averted (**Figure S1**).

232 Sensitivity analyses including all scenarios found that an annual dual RDT (scenario 2) is cost-saving in
233 59% of the simulations and either cost-saving or cost-effective (at \$2,715 per DALY averted) in all
234 simulations (**Table S2**). In non-dominated scenarios (scenarios 2, 3, and 5), using dual RDT annually or
235 biannually was cost-effective or cost-saving in most simulations, while biannual testing with one dual

236 RDT and one HIV RDT was cost-saving in only 31% of simulations (**Figure 2**). In univariate sensitivity
237 analysis adjusting costs, our scenarios that involve one dual RDT (scenarios 2 and 3) remain cost-effective
238 even after all costs (testing and treatment) are increased by 50%. In this sensitivity analysis, biannual dual
239 testing is no longer cost-effective (\$3,777 per DALY averted).

240

241 **DISCUSSION**

242 In our model, we found that implementing annual testing with the dual RDT at 75% coverage was cost-
243 saving, averted more HIV infections, and treated more syphilis cases compared to annual testing using
244 HIV RDT at 50% coverage and current syphilis testing in Viet Nam. While biannual testing with one dual
245 RDT and one HIV RDT was projected to be more costly, it would avert more HIV and syphilis related
246 DALYs and using dual RDT for both tests would avert additional DALYs attributed to syphilis. Increasing
247 the frequency of HIV testing to one or two tests per year using only HIV RDTs, while continuing to test
248 for syphilis using RPR, was not efficient compared to other strategies.

249 Implementing biannual testing substantially increases testing costs, but also prevents more HIV infections,
250 therefore averting more ART-related costs. Increasing test frequency may be cost-saving or cost-effective
251 although it incurs considerable costs in the near term while costs averted may not be observed for many
252 years. Annual testing using a dual RDT can help offset some near-term costs as it is less expensive than
253 using HIV RDT and syphilis RPR. Policymakers must weigh the health impact and cost-effectiveness of
254 different testing scenarios over time against current affordability given HIV and syphilis testing budgets;
255 however, using the dual RDT will help integrate syphilis testing within existing HIV testing programs,
256 improving program efficiencies.[19]

257 Implementation of dual RDT is occurring in some settings; preliminary reports indicate that 48% of
258 countries use dual RDT in ANC, and 25% use dual RDT in key populations, although the extent of this

259 use is unknown (WHO HIV Testing Services, 2021). PEPFAR and the Global Fund cover dual RDT in
260 ANC,[20] and there are multiple dual RDTs qualified by the Global Fund and WHO.[21] The use of dual
261 RDT during ANC could be a model for improving HIV/STI integration among those at high risk for both
262 HIV and syphilis, such as key populations, however, there are multiple operational challenges associated
263 with using dual tests, namely that of integrating HIV and STI programs.[22]

264 Benefits of the dual test are its cost-effectiveness and potential to reach more at-risk individuals. Annual
265 or biannual testing can enable earlier identification of HIV-positive individuals for faster ART initiation
266 and prevention of onward transmission. Annual HIV testing for key populations is recommended by
267 WHO, and more frequent testing (every 3-6 months) may be advised for those with individual risk factors,
268 including those using pre-exposure prophylaxis (PrEP) and key populations presenting with STIs.[23]
269 Individuals presenting with syphilis symptoms should also test for HIV, and using the dual RDT is less
270 costly as compared to a syphilis RPR and HIV RDT. As policy makers scale up PrEP among key
271 populations in Viet Nam, including at least one dual RDT in the testing algorithm may be more cost-
272 effective than using HIV RDTs alone. In addition, using dual RDT tests can facilitate lay providers to
273 offer both HIV and syphilis testing for their community.[24]

274 Our results were robust to sensitivity analyses, suggesting that testing annually or biannually using dual
275 RDTs remains cost-effective if testing costs increase and HIV prevalence decreases. In scenarios
276 involving dual RDT, the majority (>98%) of benefits, as measured in DALYs, come from averting HIV
277 infections rather than treating syphilis due to the relatively larger burden of disease from HIV than
278 syphilis. However, since the cost of a dual RDT is only slightly higher than the cost of an HIV RDT, it is
279 cheaper to use a dual RDT than separate HIV RDT and syphilis RPR tests.

280 Increased HIV testing can reduce HIV-associated morbidity and mortality and transmission from PLHIV
281 through early detection and initiation of ART. While models suggest high ART coverage would result in

282 substantial declines in HIV incidence,[25, 26] empiric data from countries with population-level viral
283 suppression exceeding 73% (e.g. Australia, eSwatini, and Thailand) have observed less significant
284 reductions in HIV incidence relative to predictions from mathematical models.[27] Similarly, when high
285 ART coverage was achieved in a series of cluster-randomized trials in sub-Saharan Africa, it resulted in
286 decreased population-level HIV incidence; however, this decrease was insufficient to end HIV as a public
287 health threat.[28–31] These discrepancies may be attributed to delayed diagnosis and ART initiation
288 following infection,[32, 33] and gaps in the 95-95-95 targets for some population groups, for example
289 young men and key populations. More frequent HIV testing strategies could increase earlier diagnosis and
290 initiation on ART, and focusing testing and linkage efforts on key populations could reduce the access
291 and coverage disparities in these groups. However, more frequent testing will also increase program costs,
292 not only through additional commodity procurement, but also for health systems, program coordination,
293 and outreach. In settings of concentrated HIV epidemics, health planners may benefit from targeting
294 limited testing resources towards high-risk groups such as key populations.

295 Dual RDTs may also increase syphilis testing frequency and coverage among key populations who are
296 more likely to access HIV testing. Previous research has shown that coupling rapid syphilis testing in
297 ANC may also increase HIV test coverage in LMICs, particularly in settings where HIV test coverage is
298 low.[34] This strategy may be similarly effective at increasing test coverage for both diseases among key
299 populations, as well as augment current ANC testing by reaching women in key populations who present
300 late or are missed by ANC services. While there is a lack of data on dual RDTs among key populations,
301 models of dual RDT during ANC have been shown to be cost-saving or cost-effective among both key
302 populations and the general population of pregnant women.[7, 35] While dual RDTs are likely more
303 effective in the context of ANC since testing can avert more adverse outcomes associated with congenital

304 syphilis and mother-to-child HIV transmission, we find dual RDTs may also be cost-effective among non-
305 pregnant key populations.

306 Our results are consistent with previously published models that show expanded testing and early access
307 to ART for key populations in Viet Nam will cost-effectively reduce the country's HIV burden.[36, 37]
308 Additionally, models from both low- and high-resource countries suggest HIV testing every 3-6 months
309 among key populations can be cost-effective in concentrated epidemics.[38][39] However, HIV risk
310 within key populations is not homogenous; further targeting of higher-risk groups within key populations
311 may be needed to achieve efficient testing regimens. While we examine the impact of increased testing
312 frequency among key populations as a whole, previous research has described the benefits of targeting
313 high-risk groups within key populations.[40] Individuals who engage in risky behaviors, such as those
314 with more sexual partners, practicing unprotected sex, or needle sharing may benefit from additional
315 testing or linkage to HIV prevention such as PrEP. Further research is needed on the optimal testing
316 intervals for higher-risk groups of key populations.

317 Approximately one-third of key populations are not aware of their HIV status. Programs focusing on HIV
318 testing and treatment among FSW and PWID in Viet Nam have shown success in reducing HIV
319 prevalence; however, less than a third of MSM reported testing for HIV in 2015, likely contributing to
320 increases in HIV prevalence among MSM in the past decade.[41] Annual syphilis testing among key
321 populations in Viet Nam is similarly low, ranging from 16% among PWID to 36% among FSW. [14–16]
322 Due to high dual prevalence of HIV and syphilis among key populations, dual testing is a promising
323 strategy to increase testing coverage and linkage to care.

324 Our analysis has several limitations. We did not include the cost of scaling-up and training providers in
325 administering dual RDTs. However, RDT are easy to use and can be administered by a lay provider, and
326 rapid results can minimize loss to follow-up. Overall, dual RDTs have been shown to have adequate

327 performance in field settings in Viet Nam among key populations.[42] Dual RDTs may also increase HIV
328 test coverage as they can be easily conducted by community health workers outside of healthcare settings,
329 and they may be more acceptable to some members of key populations who are concerned about stigma
330 associated with testing.[43] Despite this, some additional training, supervision, and support will be needed
331 to scale-up dual RDT use among key populations.

332 Some model assumptions regarding the timing of HIV and syphilis testing may be inaccurate. We assumed
333 in scenarios that included a dual RDT, additional syphilis RPR tests would not be conducted. PLWH who
334 know their status and present for syphilis screening do not need an HIV test. We assume regular testing
335 intervals for the entire population in each scenario, but it is possible people who engage in risky behaviors
336 or experience symptoms may seek more frequent retesting than biannually. We did not include the
337 increased costs of outreach to achieve increased test coverage of key populations. Considerable
338 expansions of first time testing among MSM in Viet Nam have recently been achieved through social
339 media campaigns, perhaps providing a guide for cost-effectively increasing testing uptake among key
340 populations.[41, 44] We also did not consider the burden that increasing the testing coverage and
341 frequency may have on the health system; however, as testing may be conducted effectively using lay
342 providers, increased testing may not substantially impact the provision of other services.[43] Although
343 targeting key populations in lower prevalence regions may be more difficult and costly, these results are
344 robust to increased costs and it will likely remain an effective use of resources. We assume that syphilis
345 screening will not impact syphilis prevalence rates. Increased screening may reduce prevalence by
346 increasing early treatment, but syphilis screening also has the potential to increase prevalence as
347 individuals with latent syphilis are unlikely to transmit the infection to others unless they are treated and
348 then infected again. Finally, there is limited data on population size, HIV and syphilis prevalence, and

349 health seeking behaviors among key populations. We based our model input on estimates included in
350 published literature as well as Viet Nam country sources.

351 Since data on the impact of retesting on population HIV incidence is limited, we made conservative
352 assumptions about the frequency of linkage to care and ART use following retesting. We assumed that
353 HIV testing frequency would increase in Viet Nam among key populations in the baseline scenario but
354 testing frequency would increase more quickly under the other scenarios. Because of this, we believe our
355 estimates of the impact of increased testing frequency are conservative.

356 Our study suggests that annual or biannual HIV and syphilis testing among key populations in Viet Nam
357 using a dual RDT will increase HIV and syphilis detection and treatment, while remaining cost-saving or
358 cost-effective. Integrating HIV and other STI testing can streamline services as well as expand testing and
359 help countries with epidemics concentrated in key populations reach 95-95-95 targets.

360

361 **COMPETING INTERESTS**

362 The authors declare no competing interests.

363 **FUNDING SOURCE**

364 WHO-USAID: GHA-G-00-09-00003; NIH/NIAID: K01 AI116298

365 **CONTRIBUTORSHIP STATEMENT**

366 CJ and AD devised the project and the main conceptual ideas. DC, DG, and RB parameterized the model.
367 DC and DG carried out the model implementation. VH and SVH provided model feedback. All authors
368 provided critical feedback and helped shape the research, analysis, and manuscript.

369 **DATA SHARING STATEMENT**

370 Extra data is available by emailing David Coomes, dcoomes@uw.edu

371 **References**

- 372 [1] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS update 2019 - Communities*
373 *at the centre*. Geneva, [https://www.unaids.org/en/resources/documents/2019/2019-global-](https://www.unaids.org/en/resources/documents/2019/2019-global-AIDS-update)
374 [AIDS-update](https://www.unaids.org/en/resources/documents/2019/2019-global-AIDS-update) (2019).
- 375 [2] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS Update 2020: Seizing the*
376 *moment*. Geneva, <https://www.unaids.org/en/resources/documents/2020/global-aids-report>
377 [\(2020\)](https://www.unaids.org/en/resources/documents/2020/global-aids-report).
- 378 [3] Cameron CE. Syphilis Vaccine Development: Requirements, Challenges, and Opportunities. *Sex*
379 *Transm Dis* 2018; 45: S17.
- 380 [4] Tsuboi M, Evans J, Davies E, et al. Prevalence of syphilis among men who have sex with men: A
381 global systematic review and meta-analysis from 2000 to 2020. *Lancet Glob Heal*; In press.
- 382 [5] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
383 <https://www.ncbi.nlm.nih.gov/books/NBK316021/> (2015).
- 384 [6] World Health Organization. *WHO Guideline on Syphilis screening and treatment for pregnant*
385 *women*, [https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-](https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/)
386 [screenandtreat-guidelines/en/](https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/) (2017).
- 387 [7] Rodriguez P, Roberts DA, Meisner J, et al. Cost-effectiveness of dual maternal HIV and syphilis
388 testing strategies in high and low HIV prevalence countries: a modeling study. *Lancet Glob Heal*
389 2021; 9: E61–E71.
- 390 [8] World Health Organization. *Consolidated Guidelines on the Use of Antiretroviral Drugs for*
391 *Treating and Preventing HIV Infection*. 2016. Epub ahead of print 2016. DOI:
392 [10.1017/CBO9781107415324.004](https://doi.org/10.1017/CBO9781107415324.004).
- 393 [9] UNAIDS. *90-90-90 An ambitious treatment target to help end the AIDS epidemic*,
394 <https://www.unaids.org/en/resources/909090> (2016).
- 395 [10] Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the key population
396 cascade through surveys and services to guide the HIV response. *J Int AIDS Soc* 2018; 21:

397 e25119.

- 398 [11] World Health Organization. *Global Health Sector Strategy on Sexually Transmitted Infections*
399 *2016-2021*, <https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/> (2016).
- 400 [12] World Health Organization. Global Health Observatory data repository: Data on syphilis,
401 <https://apps.who.int/gho/data/node.main.A1357STI?lang=en> (accessed 4 June 2020).
- 402 [13] Stover J, Brown T, Puckett R, et al. Updates to the Spectrum/Estimations and Projections
403 Package model for estimating trends and current values for key HIV indicators. *AIDS* 2017; 31:
404 S5–S11.
- 405 [14] Justumus P, Colby D, Mai Doan Anh T, et al. Willingness to use the Internet to seek information
406 on HIV prevention and care among men who have sex with men in Ho Chi Minh City, Vietnam.
407 *PLoS One* 2013; 8: e71471.
- 408 [15] Nguyen TA, Hoang LT, Pham VQ, et al. Risk factors for HIV-1 seropositivity in drug users under 30
409 years old in Haiphong, Vietnam. *Addiction* 2001; 96: 405–413.
- 410 [16] Ngo AD, Ratliff EA, Mccurdy SA, et al. Health-seeking behaviour for sexually transmitted
411 infections and HIV testing among female sex workers in Vietnam. *AIDS Care - Psychol Socio-*
412 *Medical Asp AIDS/HIV* 2007; 19: 878–887.
- 413 [17] Feldman J, Mishra S. What could re-infection tell us about R0? A modeling case-study of syphilis
414 transmission. *Infect Dis Model* 2019; 4: 257–264.
- 415 [18] World Bank. World Bank Data: GDP per capita (current US\$) - Vietnam,
416 <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=VN> (accessed 16 December
417 2020).
- 418 [19] Ong JJ, Fu H, Smith MK, et al. Expanding syphilis testing: a scoping review of syphilis testing
419 interventions among key populations. *Expert Rev Anti Infect Ther* 2018; 16: 423–432.
- 420 [20] U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). *PEPFAR 2021 Country and Regional*
421 *Operational Plan (COP/ROP) Guidance for all PEPFAR Countries*, [https://www.state.gov/wp-](https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf)
422 [content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf](https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf) (2021).

- 423 [21] The Global Fund. *List of HIV Diagnostic test kits and equipments classified according to the*
424 *Global Fund Quality Assurance Policy*,
425 https://www.theglobalfund.org/media/5878/psm_productshiv-who_list_en.pdf (2021).
- 426 [22] Broyles LN, Boeras D, Peeling RW. Implementation of dual maternal HIV-Syphilis testing: The
427 devil is in the details. *Lancet Glob Heal* 2021; 9: e595.
- 428 [23] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
429 <https://www.who.int/publications/i/item/978-92-4-155058-1> (2019).
- 430 [24] Nguyen V, Anh L, Thong N, et al. High prevalence of HIV, syphilis and HCV among key
431 populations and partners: results from an integrated multiple diseases testing led by community
432 in Viet Nam. In: *Poster exhibition IAS 2019*. Mexico City, Mexico, 2019.
- 433 [25] Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral
434 therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet* 2009;
435 373: 48–57.
- 436 [26] Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: Systematic comparison of
437 mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South
438 Africa. *PLoS Med*; 9. Epub ahead of print July 2012. DOI: 10.1371/journal.pmed.1001245.
- 439 [27] UNAIDS. AIDSinfo | UNAIDS, <https://aidsinfo.unaids.org/> (accessed 27 May 2020).
- 440 [28] Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in
441 rural South Africa: a phase 4, open-label, community cluster randomised trial. *Lancet HIV* 2018;
442 5: e116–e125.
- 443 [29] Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and
444 Incidence of HIV Infection in Botswana. *N Engl J Med* 2019; 381: 230–242.
- 445 [30] Havlir D V., Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a
446 Community Health Approach in Rural Africa. *N Engl J Med* 2019; 381: 219–229.
- 447 [31] Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence —
448 HPTN 071 (PopART). *N Engl J Med* 2019; 381: 207–218.

- 449 [32] Akullian A, Bershteyn A, Jewell B, et al. The missing 27%. *AIDS* 2017; 31: 2427–2429.
- 450 [33] Abdool Karim SS. HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. *N Engl J Med*
451 2019; 381: 286–288.
- 452 [34] Swartzendruber A, Steiner RJ, Adler MR, et al. Introduction of rapid syphilis testing in antenatal
453 care: A systematic review of the impact on HIV and syphilis testing uptake and coverage. *Int J*
454 *Gynecol Obstet* 2015; 130: S15–S21.
- 455 [35] Gliddon HD, Peeling RW, Kamb ML, et al. A systematic review and meta-analysis of studies
456 evaluating the performance and operational characteristics of dual point-of-care tests for HIV
457 and syphilis. *Sex Transm Infect* 2017; 93: S3–S15.
- 458 [36] Kato M, Long NH, Duong BD, et al. Enhancing the Benefits of Antiretroviral Therapy in Vietnam:
459 Towards Ending AIDS. *Curr HIV/AIDS Rep* 2014; 11: 487–495.
- 460 [37] Kato M, Granich R, Bui DD, et al. The potential impact of expanding antiretroviral therapy and
461 combination prevention in Vietnam: Towards elimination of HIV transmission. *J Acquir Immune*
462 *Defic Syndr*. Epub ahead of print 2013. DOI: 10.1097/QAI.0b013e31829b535b.
- 463 [38] Kazemian P, Costantini S, Kumarasamy N, et al. The Cost-effectiveness of Human
464 Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk
465 Groups in India. *Clin Infect Dis* 2020; 70: 633–642.
- 466 [39] Cipriano LE, Zaric GS, Holodniy M, et al. Cost Effectiveness of Screening Strategies for Early
467 Identification of HIV and HCV Infection in Injection Drug Users. *PLoS One*. Epub ahead of print
468 2012. DOI: 10.1371/journal.pone.0045176.
- 469 [40] Reitsema M, Steffers L, Visser M, et al. Cost-Effectiveness of Increased HIV Testing among MSM
470 in The Netherlands. *AIDS* 2019; 33: 1807–1817.
- 471 [41] Green KE, Vu BN, Phan HT, et al. From conventional to disruptive: upturning the HIV testing
472 status quo among men who have sex with men in Vietnam. *J Int AIDS Soc* 2018; 21: e25127.
- 473 [42] Withers K, Bristow C, Nguyen M, et al. A field evaluation of a rapid dual immunoassay for human
474 immunodeficiency virus and syphilis antibodies, Hanoi, Vietnam. *Int J STD AIDS* 2019; 30: 173–

475 180.

- 476 [43] Vu BN, Green KE, Phan HTT, et al. Lay provider HIV testing: A promising strategy to reach the
477 undiagnosed key populations in Vietnam. *PLoS One* 2018; 13: e0210063.
- 478 [44] Nguyen VTT, Phan HTT, Kato M, et al. Community-led HIV testing services including HIV self-
479 testing and assisted partner notification services in Vietnam: lessons from a pilot study in a
480 concentrated epidemic setting. *J Int AIDS Soc* 2019; 22: e25301.
- 481 [45] Clatts MC, Goldsamt LA, Giang LM, et al. Sexually transmissible infection and HIV prevention and
482 treatment for young male sex workers in Vietnam: Findings from the SHEATH intervention. *Sex*
483 *Health*. Epub ahead of print 2016. DOI: 10.1071/SH16051.
- 484 [46] Bao A, Colby DJ, Trang T, et al. Correlates of HIV Testing Among Transgender Women in Ho Chi
485 Minh, Vietnam. *AIDS Behav*. Epub ahead of print 2016. DOI: 10.1007/s10461-016-1574-8.
- 486 [47] Magnani R, Riono P, Nurhayati, et al. Sexual risk behaviours, HIV and other sexually transmitted
487 infections among female sex workers in Indonesia. *Sex Transm Infect*. Epub ahead of print 2010.
488 DOI: 10.1136/sti.2009.038059.
- 489 [48] Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using
490 incidence-based disability-adjusted life years (DALYs): Results from the burden of communicable
491 diseases in Europe study, European Union and European economic countries, 2009 to 2013.
492 *Eurosurveillance*. Epub ahead of print 2018. DOI: 10.2807/1560-7917.ES.2018.23.16.17-00454.
- 493

494 **FIGURE LEGENDS**

495 **Figure 1. Efficiency frontier presenting the total disability adjusted life years (DALYs) and costs for**
496 **five testing scenarios among key populations.** The solid line indicates the scenarios that are not
497 dominated by other scenarios. Dominated indicates that a scenario is either more costly and less effective
498 or has a higher ICER than a scenario that is more effective. The ICERs for the non-dominated scenarios
499 are shown. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio, RDT=rapid
500 diagnostic test, USD=United States dollars

501


502

503

504 **Figure 2. Sensitivity analysis of non-dominated scenarios using a Monte Carlo simulation of the**
505 **cost effectiveness of HIV/syphilis dual testing among key populations in Viet Nam.** Plot shows 10,000
506 iterations in which 17 key parameters were randomly adjusted. All points below the green line are cost-
507 effective at \$2,715 per DALY averted and those below the solid black line (y-intercept) are cost-saving.
508 Only non-dominated scenarios are shown in this figure; cost-effectiveness of *1 Dual Test* is compared to
509 baseline, *1 HIV Test & 1 Dual Test* is compared to *1 Dual Test*, and *2 Dual Tests* is compared to *1 HIV*
510 *Test & 1 Dual Test*. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio,
511 RDT=rapid diagnostic test, USD=United States dollars.


512

513



Scenario

- Baseline
- 1 dual HIV/syphilis RDT
- 1 HIV RDT
- 1 dual & 1 HIV RDT
- 2 HIV RDTs
- 2 dual HIV/syphilis RDTs



Scenario

- 1 dual HIV/syphilis RDT
- 1 dual & 1 HIV RDT
- 2 dual HIV/syphilis RDTs

ICER=\$2,715